About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, September 24th, 2013

The QualityStocks
Daily Stock List

graphic
graphic

Be Active Holdings, Inc. (JALA)

MassiveStockProfits, PennyStocks24, Stock Stars, and MonsterStocksPick reported earlier on Be Active Holdings, Inc. (JALA), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Be Active Holdings, Inc. is a manufacturer and marketer of frozen Greek yogurt under the Jala brand (Jala Bars). The Company provides their products through retail stores in the northeast regions of New York, New Jersey, Connecticut, Massachusetts, Rhode Island, Maine, Pennsylvania, and Ohio. All Natural Jala Frozen Yogurt Bars are the latest product from Marc Wexler and Sam Pugliese. They are the creators of Skinny Cow Ice Cream Bars. Incorporated in 2009, Be Active Holdings has their headquarters in New York, New York.  

The Company makes Jala bars with naturally fermented yogurt using Streptococcus thermophilus and Lactobacillus bulgaricus yogurt cultures. In addition, they add Lactobacillus acidophilus and Lactobacillus delbrueckii bulgaricus bacteria. Each Jala bar is 110 calories. All three yogurt bars are rich in antioxidants and probiotics. They are also a good source of calcium. Jala Chocolate Fudge Bars are one of the first ice cream products worldwide to feature the potential health benefits of probiotics.

Jala Bars contain antioxidants and bacteria flora. Each bar contains approximately 10 percent of the Recommended Daily Allowance for calcium. They also contain approximately one third of the Recommended Daily Allowances of Vitamins A, C and E. The Company's products include Low Fat Greek Frozen Yogurt Bars (Chocolate Fudge, Vanilla Blueberry Swirl, and Vanilla Pomegranate Swirl). The Jala Bars have no artificial sweeteners or flavors and the bars are now available in more than 2,500 stores.

In addition, Be Active Holdings offers Low Fat Greek Frozen Yogurt Sandwiches. Flavors include Vanilla, Vanilla and Chocolate Combo, and Vanilla and Strawberry Swirl. Each Jala sandwich contains 140 calories. The Company’s products also include Low Fat Greek Frozen Yogurt Pints. Jala pints contain vitamins, antioxidants, as well as active probiotics. Pint flavors include Blueberry Patch, Chocolate Chip Eclipse, Honey Vanilla Harmony, Peanut Butter Blaze, Pomegranate Passion, Strawberry Dreams, and Vanilla Bean Bliss.

Be Active Holdings, Inc. (JALA), closed Tuesday's trading session at $0.033, down 2.94%, on 168,988 volume with 17 trades. The average volume for the last 60 days is 101,080 and the stock's 52-week low/high is $0.006/$1.20.

Sustainable Environmental Technologies Corp. (SETS)

AllPennyStocks reported previously on Sustainable Environmental Technologies Corp. (SETS), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Headquartered in Upland, California, Sustainable Environmental Technologies Corp. (SETS), via their subsidiaries, acquires, develops, and markets strategic technologies that responsibly and economically solve environmental issues. The Company’s offerings include treatment, recovery, reclamation, and re-injection services for produced water from oil and gas production. Their offerings also include ultra-efficient tri-gen systems that offer combined cooling, heating, and power generation with the added capability of water production from a single energy source. SETS’ shares trade on the OTCQB.

The Company also offers design, construction, management, operation, and maintenance services. In addition, SETS offers equipment manufacturing services for industrial and municipal sectors. Their principal products include the Centerline SWD System, and the DynIX technology. The Company’s solutions also include Blue Bench. SETS’ technologies deliver crucial resources for business operations while reducing their customers' environmental impact and conserving essential and diminishing resources.

The foundation of SETS’ Centerline SWD™ facilities are on the strategic utilization and placement of patented and best in class technology that maximize the purification and separation processes. This model allows for the separation of 99 percent of any remaining oil residue in the produced water. Furthermore, it allows for the proper cleaning and preparation of the water for either deep injection into the earth or reselling of the cleaned and treated water for frak and other oil field processes.

The Company’s DynIX is a fixed bed dynamic flow ion exchange system. The design of it was originally specially for signature characteristics of Coal Bed Methane (CBM) produced water and deployed in Wyoming’s Powder River Basin. SETS’ proprietary technology has considerably reduced the waste stream to less than four percent of treated water volume.

SETS’ solutions include the aforementioned Blue Bench.  Pro Water, LLC, through their Blue Bench Deep Injection Well (DIW), has an established client base that generates positive monthly cash flow. This will allow SETS to fund additional technology acquisitions. Pro Water is scheduled to start construction of a full research and development laboratory. When completed, this multi-acre facility will serve as a showplace for potential customers and a technology incubator that cultivates new and upcoming ventures that can be proven and then brought into SETS.

Sustainable Environmental Technologies Corp. (SETS), closed Tuesday's trading session at $0.085, even for the day. The average volume for the last 60 days is 10,744 and the stock's 52-week low/high is $0.07/$0.50.

Royal Mines & Minerals Corp. (RYMM)

PennyStockRumors, SmallCapVoice, Nebula Stocks, FeedBlitz, and MicrocapVoice reported previously on Royal Mines & Minerals Corp. (RYMM), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Incorporated on December 14, 2005, under the laws of the State of Nevada, Royal Mines & Minerals Corp. engages in the acquisition, exploration, and development of mineral properties. The Company explores for copper, silver, and gold. An exploration stage company, Royal Mines & Minerals has their corporate headquarters in Henderson, Nevada. The Company’s shares trade on the OTC Markets’ OTCQB.

Royal Mines & Minerals’ principal objectives are to commercially extract and refine precious metals from their own and others mineralized materials; use their Cholla leaching process to recover precious metals from specific ore bearing materials; and joint venture, acquire, as well as develop mining projects in North America. The Company has been laboratory and pilot testing the Cholla process since September 2010. Independent bench scale tests have validated that Royal Mines & Minerals is exposing recoverable gold using their process.

The Company has run more than 50 tons of coal fly ash. They have experienced in-house values ranging from traces of gold to multiple ounces of gold per ton. They can reproduce metal in hand process tests, which they are scaling up. The Company’s plan is to work with strategic partners to scale up the Cholla process and expand production to multiple locations.

Royal Mines & Minerals is focusing their business on commercially processing specific fly ash and other mineable materials, using a leach process that exposes extractable gold (the aforementioned Cholla Process) at the Company’s processing and refining plant in Scottsdale, Arizona. They temporarily shut down their Phoenix Facility in November of 2012 until they receive the required funding to continue that operation. The Company is looking to enter into joint ventures with third parties who have legal rights to fly ash resources; this includes landfills/monofills.

Furthermore, Royal Mines & Minerals entered into a Memorandum of Understanding (MOU) dated October 19, 2010, with Golden Anvil, SA de CV concerning the proposed formation and funding of a proposed joint venture for the exploration and development of mineral concessions owned by Golden Anvil in the State of Nayarit, Mexico (the Golden Anvil Mine).

Royal Mines & Minerals Corp. (RYMM), closed Tuesday's trading session at $0.0308, even for the day, on 20,000 volume with 1 trade. The average volume for the last 60 days is 40,703 and the stock's 52-week low/high is $0.0002/$0.0349.

TranSwitch Corp. (TXCC)

StreetInsider, UltimatePennyStock, Greenbackers, and Stock Analyzer reported earlier on TranSwitch Corp. (TXCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 1988, OTCQB-listed TranSwitch Corp. is a semiconductor solutions provider based in Shelton, Connecticut. The Company is a foremost provider of semiconductor solutions in the fast growing consumer electronics and telecommunications markets. TranSwitch provides innovative integrated circuit (IC) and intellectual property (IP) solutions. These solutions deliver core functionality for video, voice, and data communications equipment for the customer premises and network infrastructure markets. TranSwitch’s customers are leading consumer electronics and telecommunications equipment companies worldwide. The Company has a broad portfolio of IP products, and worldwide patents held in 22 countries.

The Company’s mission is to help OEMs and ODMs to transform best-in-class voice and video quality for the next generation multimedia over IP. This is while providing the complete software platform and customer support required for the fastest time-to-market. The Company’s solutions serve broadband wireless and wireline markets. Their specialities include IC & IP solutions for HDTV and 3D-TV High Speed Interconnect; Communications Processors-based solutions for IP Multimedia CPE; and Multicore Processor SoC and software solutions for Fixed, 3G/LTE/4G Mobile Infrastructure.

For the customer-premises market, TranSwitch offers multi-standard, high-speed interconnect solutions. These enable the distribution and presentation of high-definition (HD) video and data content for consumer electronics applications. In addition, the Company provides a family of best-in-class communications processors.

For the network infrastructure market, the Company provides integrated multi-core network processor System-on-a-Chip (SoC) solutions. These solutions are for Fixed, 3G and 4G Mobile, VoIP, as well as Multimedia applications.

Recently, TranSwitch confirmed the closing of the Company’s previously announced $2.5 million equity investment from Ilex Partners, LLC, managed by Mr. Michael Steinhardt. Proceeds from the transaction will be used for general corporate and working capital purposes. TranSwitch offers their products directly in North America, Taiwan, China, Japan, Korea, and Europe, and through a network of distributors in North America, Asia, and Europe.

TranSwitch Corp. (TXCC), closed Tuesday's trading session at $0.21, down 4.55%, on 132,730 volume with 40 trades. The average volume for the last 60 days is 120,861 and the stock's 52-week low/high is $0.15/$0.30.

Dethrone Royalty Holdings, Inc. (DRHC)

PennyStocks24 reported earlier on Dethrone Royalty Holdings, Inc. (DRHC), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Dethrone Royalty Holdings, Inc., through their wholly owned subsidiary, Dethrone Beverage Co., engages in the manufacture and sale of sports performance or energy drinks, and other non-alcoholic beverages under the Dethrone Beverages trade name in the U.S. Founded in 1997, Dethrone Royalty Holdings has their corporate headquarters in Cave Creek, Arizona. The Company’s shares trade on the OTC Markets’ OTCQB. 

Dethrone Royalty has been a major factor in the growth of the Mixed Martial Arts (MMA) sports field. The Dethrone Royalty brand formed in 2009 and its foundation is on the traditions of ancient kings. Mr. Nick Swinmurn is behind the success of Dethrone Royalty. He was Founder of Zappos.com and is part owner of the NBA team the Golden State Warriors.

The careful formulation of Dethrone’s sport beverages are to support mental focus and help increase blood flow, thus giving the body the fuel needed to get through a particular event or throughout the day. Dethrone beverages are sugar free and extremely low in calories and caffeine. The design of the Company’s unique blends are to bridge the gap between energy, supplements, and hydration drinks. This is to widen their appeal and expand the Company’s target market.  

The Company is broadening their appeal beyond the world of Mixed Martial Arts (MMA) and the UFC (Ultimate Fighting Championship) through entering into Endorsement deals with superstar athletes from the NFL, MLB, NHL, and NBA. They are also sponsoring major sporting events and social causes. Dethrone Royalty will produce and distribute lines of shirts/clothing for each sports figure signed as endorsers by the Company and market the shirts via their normal distribution channels. Dethrone will receive commissions equal to 12.5 percent of net sales generated by the shirts.

Dethrone commenced distribution of their product as of the first calendar quarter of 2013. The Company currently has two flavors of one product and they will distribute in California to convenience stores, gas stations, grocery stores, as well as gyms. Presently, Dethrone works with a beverage manufacturer in Florida and a number of companies for packaging materials.

This month, Dethrone Royalty Holdings announced the endorsements of two additional professional athletes with Professional NHRA Funny Car Drag Racer Ron Capps and NFL Pittsburgh Steelers running back Isaac Redman. Mr. Michael Holley, Dethrone Royalty Holding's President, stated, "Both athletes are welcomed additions to the Dethrone family of athletic endorsers who now currently stand at eight."

Dethrone Royalty Holdings, Inc. (DRHC), closed Tuesday's trading session at $0.03, up 15.38%, on 100,167 volume with 7 trades. The average volume for the last 60 days is 28,168 and the stock's 52-week low/high is $0.0065/$0.26.

Western Capital Resources, Inc. (WCRS)

Winning Penny Stock Picks, WePickPennyStocks, Super Hot Penny Stocks, Super Nova Stock Picks, RisingPennyStocks, Penny Stock Pick Report, Penny Stock Pick Alert, Penny Stock MoneyTrain, Liquid Tycoon, Joe Penny Stocks, PennyPickAlerts, Pumps and Dumps, PennyStocks24, Penny Investor Network, Penny Stock Rumble, Stock Edge, Premier Equity Reports, and Your Stock Alert reported on Western Capital Resources, Inc. (WCRS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Western Capital Resources, Inc., through their subsidiaries, provides consumer financial services and retails cellular phones to individuals chiefly in the Midwestern U.S. Western Capital Resources operates in two segments, which are Consumer Finance and Cellular Retail. The Company is based in Omaha, Nebraska and their shares trade on the OTCQB.

Consumer finance operations are conducted under Western Capital Resources’ wholly owned subsidiaries, Wyoming Financial Lenders, Inc. and Express Pawn, Inc., principally in the Midwestern and Southwestern U.S. Services provided include short-term loans, check cashing, as well as other money services. Services provided also include title loans and other ancillary consumer financial products and services that are complementary to their cash advance-lending business. These include check-cashing services, money transfers, and money orders. For the Company’s check cashing business, they mainly cash payroll checks. In addition, they cash government assistance, tax refund, and insurance checks or drafts.

Western Capital Resources operated 51 "payday" stores, one payday/pawn store, and one pawn store in nine states (Colorado, Iowa, Kansas, Nebraska, North Dakota, South Dakota, Utah, Wisconsin and Wyoming) as of June 30, 2013.

Pertaining to Western Capital Resources’ Cellular retail operations, these are conducted under the Company’s wholly owned subsidiary, PQH Wireless, Inc. This division operates retail stores selling cellular phones and accessories. The Company is an authorized Cricket dealer selling cellular phones and accessories, providing ancillary services and accepting service payments from customers.

Their cellular phone offerings include prepaid cellular phone service that functions for a time period for a flat fee, without usage limitations and without any long-term contract or commitment required from the consumer. As an authorized premier Cricket dealer, Western Capital Resources is only permitted to sell the Cricket line of prepaid cellular phones at their Cricket retail stores. The Company operated 52 Cricket wireless retail stores in 14 states (Arizona, Colorado, Idaho, Illinois, Indiana, Iowa, Kansas, Missouri, Nebraska, Ohio, Oklahoma, Oregon, Texas and Washington) as of June 30, 2013.

Western Capital Resources, Inc. (WCRS), closed Tuesday's trading session at $0.08, up 23.08%, on 2,001 volume with 3 trades. The average volume for the last 60 days is 28,992 and the stock's 52-week low/high is $0.021/$0.3758.

Aeolus Pharmaceuticals, Inc. (AOLS)

TaglichBrothers and Ceocast News reported earlier on Aeolus Pharmaceuticals, Inc. (AOLS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Based in Mission Viejo, California, Aeolus Pharmaceuticals, Inc. is a biotechnology company developing compounds to protect against radiological and chemical threats. The Company is developing a platform of a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Their first compound is AEOL 10150. Aeolus Pharmaceuticals lists on the OTC Markets’ OTCQB.

The Company’s AEOL 10150 is undergoing development, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons. Its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure.

Aeolus Pharmaceuticals’ strategy is to take advantage of the considerable investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to efficiently develop the compound for use in oncology.

AEOL 10150 is a broad-spectrum catalytic antioxidant. It is specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure.

AEOL 10150 has performed well in animal safety studies. It was well-tolerated in two human clinical trials. In addition, it has demonstrated statistically significant survival efficacy in multiple Lung-ARS studies in animals. Moreover, AEOL 10150 is presently in development for use as a therapeutic and prophylactic drug in cancer patients.

Last week, Aeolus Pharmaceuticals announced that the Biomedical Advanced Research and Development Authority (BARDA) exercised $6.0 million in additional contract options under their advanced research and development contract for AEOL-10150. Aeolus is developing their lead compound, AEOL-10150, as a treatment for the pulmonary syndrome of Acute Radiation Syndrome (Lung-ARS) and delayed effects of acute radiation exposure (DEARE) under a five year contract with BARDA worth up to $118MM. The contract was awarded on February 11, 2011.  BARDA is a division of the U.S. Department of Health and Human Services that manages the advanced development and purchase of medical countermeasures for public health threats. 

At present, AEOL 10150 is additionally being studied by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal tract and by NIH CounterACT as a countermeasure against chlorine gas and sulfur mustard gas exposure.

The Company has selected AEOL 11207 as their second development candidate.  Data collected to date suggest that AEOL 11207 may be useful as a potential once-every-other-day oral therapeutic treatment option for central nervous system (CNS) disorders, most probably Parkinson’s disease.

Aeolus Pharmaceuticals, Inc. (AOLS), closed Tuesday's trading session at $0.28, up 7.69%, on 30,950 volume with 13 trades. The average volume for the last 60 days is 47,152 and the stock's 52-week low/high is $0.22/$0.475.

All Grade Mining, Inc. (HYII)

PennyStocks24, Pumps and Dumps, OtcWizard, SizzlingStockPicks, Wallstreetlivechat, RockingPennyStocks, Pennystocktweeters.com, Center Stage Stocks, Fast Moving Stocks, and StockMister reported on All Grade Mining, Inc. (HYII), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, All Grade Mining, Inc. is a development-stage company focused on the extraction of iron ore. The Company’s mission is to acquire mining concessions in all phases, all sizes, and all minerals. All Grade Mining is presently concentrating on the extraction of iron ore in South America, mainly in Chile. The Company has put together a team of experts in mining and logistics.
 
All Grade Mining has their corporate headquarters in Hackensack, New Jersey. The Company previously went by the name Hybred International, Inc. They changed their name to All Grade Mining, Inc. in November of 2011.

At present, All Grade Mining owns the Salitrosa Iron Ore Mine. They acquired the Salitrosa iron mine in Chile in October of 2011, as the first mining project of the Company. The Salitrosa mine is 28 kms from Chanaral and 60 kms from the Caldera port. It consists of an updated 741 hectares covering 24 square kms. It has an estimated iron ore reserve of more than 40 million metric tons based on magnometric and geological studies done on the property.

All Grade Mining expects to bring production up to 150,000 metric tons each month. The Salitrosa project would involve an open pit mine and a dry magnetic concentration plant for the production of 200,000 tons/month of iron ore concentrates with an average grade of 63.5 percent.

Earlier this month, All Grade Mining announced that they finalized the acquisition of the Plateada Copper Sulfide Project, a 90 hectare property approximately 55 kms southeast of Ovalle, Chile, in the commune of Combarabala. Company Management anticipates the Plateada project will become cash flow positive within seven to nine months.

The Company decided to acquire the Plateada Project from their primary contractor, Foreign Commerce Consulting, after the property produced 500 tons per month of high grade copper sulfide and superficial copper oxides while showing a significant presence of other trace elements such as gold and silver over the past two years.

All Grade Mining, Inc. (HYII), closed Tuesday's trading session at $0.0002, up 100.00%, on 35,655,156 volume with 67 trades. The average volume for the last 60 days is 84,576,860 and the stock's 52-week low/high is $0.0001/$0.077.

graphic

The QualityStocks
Company Corner

graphic
graphic

Nexus Enterprise Solutions, Inc. (NXES)

The QualityStocks Daily Newsletter would like to spotlight Nexus Enterprise Solutions, Inc. (NXES). Today, Nexus Enterprise Solutions, Inc. closed trading at $0.30, even for the day. The stock’s average daily volume over the past 60 days is 648, and its 52-week low/high is $0.26/$0.31.

Nexus Enterprise Solutions, Inc. announced the addition today of Stan Rapp, widely recognized as one of the country's most influential marketing executives, to the company's board of directors. Rapp is a marketing icon who has twice served as CEO of global advertising agencies with combined revenues now reaching more than a billion dollars, most recently founding Engauge, an agency that swiftly became one of the country's most successful social media agencies, serving such clients as Coca Cola, UPS, Home Depot, Cisco, Nationwide and Wells Fargo.

Nexus Enterprise Solutions, Inc. (NXES) focuses on the auto, health, and life insurance lead generation business. The company markets its services to agencies, agent networks, and insurance carriers throughout the United States. Lead campaigns are fully customizable based on the need of the buyer whether it’s geo-targeting, specific age demographics, or whatever the carrier or agency requires.

The company leverages a suite of proprietary processes and systems designed to identify customers that are more likely to grow with its clients beyond a single transaction. Nexus Enterprise is a recognized leader in providing a broad range of internet marketing strategies to capture targeted buyer data and use that data to generate revenues through both affiliate marketing and lead generation sales.

By working with multiple carriers and agencies, Nexus Enterprise ensures lead coverage throughout the United States. The company provides real-time reporting and its payment schedule can be structured either on a weekly or monthly schedule. Additionally, all traffic is hosted and run on its own landing pages and websites, which the company has done extensive A/B and multivariate testing to ensure optimization for peak performance.

The team of individuals behind Nexus Enterprise has a tremendous amount of experience and success in lead generation. Holding fast to the belief that top quality leads are necessary for a top quality company, the company’s staff implements its in-house expertise with PPC, SEO, social networking, and e-mail traffic to generate the best real-time leads for Nexus Enterprise’s growing list of clients. Disclaimer

Nexus Enterprise Solutions, Inc. Company Blog

Nexus Enterprise Solutions, Inc. News:

Nexus Enterprise Solutions, Inc. Elects Marketing Icon Stan Rapp to Board of Directors

Nexus Enterprise Solutions, Inc. Elects Gunnar Counselman to Board of Directors

Nexus Enterprise Solutions, Inc. Reports Record, 300% Increase in Insurance Leads Generated by its Proprietary NexChange Marketplace(sm)

OxySure Systems, Inc. (OXYS)

The QualityStocks Daily Newsletter would like to spotlight OxySure® Systems, Inc. (OXYS). Today, OxySure Systems, Inc. closed trading at $0.79, up 1.28%, on 8,800 volume with 4 trades. The stock’s average daily volume over the past 60 days is 6,894, and its 52-week low/high is $0.35/$2.75.

OxySure Systems, Inc. announced progress with regard to the CE Marking of its flagship product, the OxySure Model 615, an FDA-approved solution to produce medically pure oxygen from dry, inert powders for emergency/short duration use. The Company received notice on September 12, 2013 of an opinion rendered by the Medicines and Healthcare products Regulatory Authority (MHRA) in the United Kingdom related to the classification of the OxySure Model 615 as a medical device, a major forward in the CE Marking process.

OxySure Systems, Inc. (OXYS) is a medical technology company focused on developing, manufacturing, and distributing specialty respiratory and medical solutions. The company has developed a unique platform technology that instantly creates medically pure oxygen from two dry, inert powders, allowing oxygen to be delivered on demand. This cutting-edge technology has already been granted FDA-approved for commercial sale.

The company is targeting multiple enormous end markets with no direct competition. OxySure initially plans to focus on the 102,265 educational campuses, 350,735 manufacturing facilities, 350,000 churches, 12 million recreational vehicles (RVs), 8 million boats and yachts, 950,000 restaurants, and hundreds of thousands of other commercial and municipality facilities in the U.S. Outside the US, OxySure has also already signed significant distribution agreements, including Australia, New Zeeland, the United Kingdom, the Netherlands, Luxembourg, Belgium, Brazil, and South Africa. OxySure’s potential market is at least as large as AEDs and potentially as large as fire extinguishers, which together total at least 500+ million units worldwide.

OxySure’s flagship product, OxySure Model 615, introduces the first new oxygen technology in 50 years. There are no compressed tanks, no dials, no valves, no regulatory maintenance, no hydrostatic testing, no batteries, and no required training, and the technology is both safe and easy-to-use for the layperson. It can be placed virtually anywhere to help save lives by bridging the gap between a medical emergency and the arrival of first responders on the scene.

The company aims to capitalize on market opportunities primarily through partnerships with distributors and OEM customers. Protected by numerous issued patents and patents pending, the company’s products are available over-the-counter without the need for a prescription and has already saved thousands of lives around the globe during various types of medical emergencies. Disclaimer

OxySure Systems, Inc. Company Blog

OxySure Systems, Inc. News:

OxySure Systems, Inc. Announces Progress on CE Marking

The Stock Radio Interviews OxySure Systems’ CEO, Highlighting Life Saving “Oxygen from Powder” Technology

Taglich Brothers Reiterates Speculative Buy Rating on OxySure Systems, Inc.

VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.89, up 58.93%, on 5,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 1,991, and its 52-week low/high is $0.50/$0.95.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Provides Update on $36 Million Strategic Financing Agreement

VistaGen Therapeutics Presents CardioSafe 3D™ and LiverSafe 3D™ Developments at International Society of Stem Cell Research's 11th Annual Meeting

VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue

Mabwe Minerals Inc. (MBMI)

The QualityStocks Daily Newsletter would like to spotlight Mabwe Minerals Inc. (MBMI). Today, Mabwe Minerals Inc. closed trading at $0.35, up 16.67%, on 8,705 volume with 6 trades. The stock’s average daily volume over the past 60 days is 19,528, and its 52-week low/high is $0.06/$0.70.

Mabwe Minerals Inc. (MBMI) is a U.S. based natural resources and hard asset company focused on the mining, logistics, and commercial sales of industrial minerals and metals, with a particular emphasis on barite. The company's operations are conducted through its Zimbabwe affiliate, Mabwe Mineral Zimbabwe (Private) Ltd. Transitioning into commercial production, MBMI's company fundamentals are well positioned with virtually no debt and key strategic partnerships in place.

Along with its affiliate, Mabwe Minerals Zimbabwe (Private) Ltd., an indigenous Zimbabwe company, the company owns 100% of the mineral & metal rights to Dodge Mine. The mine will be managed by the company's minority owned partner, WGB Kinsey & Company, Zimbabwe's most experienced mining & construction company representing four generations of Kinsey leadership. Management believes WGB Kinsey & Company has all the necessary equipment and management experience to efficiently perform all the mining operations at Dodge Mine.

The Dodge Mine property consists of three hydrothermal mountains representing 123 hectares containing multiple deposits of superior-grade barite, limestone, and talc. Hydrothermal barite deposits throughout Dodge Mine represent the highest grade of new barite sources to be brought into commercial production in years. A third party oil & gas drilling sector geologist recently confirmed that the multiple barite deposits are considered "World Class" in quality and highly efficient to mine via open pit extraction following the barite veins and salvaging large percentages of barite within the halo zones via jigging systems.

With a continuing worldwide shortage of high-grade barite, Mabwe Minerals is in the right place at the right time. The company's current customer uses barite as a weighting agent in oil & gas drilling applications in the Gulf of Mexico, home to the largest concentration of active rigs in the world. Coupled with the recent massive discovery of oil & gas off the coast of neighboring Mozambique along with new drilling contracts expected in the region, MBMI is in an attractive geographical location to capture the expected demands of this emerging market. Moving from an exploration stage company into commercial barite production, Mabwe Minerals is well positioned to generate significant shareholder returns. Disclaimer

Mabwe Minerals Inc. Company Blog

Mabwe Minerals Inc. News:

Mabwe Minerals Completes Strategic Alliances With Steinbock Minerals Ltd. and Yasheya Ltd.

Mabwe Minerals Commences Mining Operations at Dodge Mine

Mabwe Minerals Frames Strategic Alliances With Steinbock Minerals Ltd. and Yasheya Ltd.

Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $7.00, up 10.24%, on 65,269 volume with 166 trades. The stock’s average daily volume over the past 60 days is 23,828, and its 52-week low/high is $2.60/$19.375.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis Lead Product Candidate ADXS-HPV in Combination with PD-1 Antibody Significantly Improves Immune and Therapeutic Efficacy in Preclinical Study

Advaxis Announces Three Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer Annual Meeting

Advaxis Appoints Daniel J. O’Connor President and CEO and Elects Dr. James Patton Non-Executive Chairman of the Board

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.15, up 6.38%, on 722,301 volume with 94 trades. The stock’s average daily volume over the past 60 days is 490,297, and its 52-week low/high is $0.13/$0.41.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation Advances Parkinson's Disease Program Towards IND Stage

International Stem Cell Corp. to Present at Rodman & Renshaw 15th Annual Global Investment Conference September 8th to 10th

International Stem Cell Corporation Enters Into Clinical Research Agreement for Parkinson's Disease Program

Dragon Capital Group Corp. (DRGV)

The QualityStocks Daily Newsletter would like to spotlight Dragon Capital Group Corp. (DRGV). Today, Dragon Capital Group Corp. closed trading at $0.0014, up 16.67%, on 14,100 volume with 2 trades. The stock’s average daily volume over the past 60 days is 4,222,784 and its 52-week low/high is $0.001/$0.01.

Dragon Capital Group Corp. (DRGV) operates through its six subsidiaries in the People's Republic of China with a specific focus on the technology market. Serving as a conduit between Chinese high-growth companies and Western investors, the company provides support in the critical functions of general business consulting, formation of joint ventures, access to capital, merger & acquisition, business valuation, and revenue growth strategies.

The development of wireless applications and business solutions is a large area of focus. Two companies Dragon has acquired are among the leading providers of mobile applications and business software in China. Shanghai Zhaoli, one of these two companies, recently received a Ten Year Outstanding Contribution Award from HP to recognize the distinguished contribution made as HP's foreign authorized distributor in Greater China Region.

Through its subsidiaries, Dragon represents a wide array of name brand manufacturers, including Hewlett Packard, Epson, Canon, Ricoh, Brother, Star, and Samsung. Dragon’s seasoned professionals have experience with both the laws and business practices of China. This experience serves as a competitive advantage for Dragon’s portfolio companies.

Dragon aims to emerge as a significant force in the high-tech sector of China. Employing expertise of Chinese and U.S. business practices, Dragon is establishing a successful track record nurturing Chinese companies. The company’s unique combination of professionals represents a powerful resource critical to maintaining and accelerating its growth. Disclaimer

Dragon Capital Group Corp. Blog

Dragon Capital Group Corp. News:

Dragon Capital Group Subsidiary to Participate in National Science and Technology Research Project Focusing on Large Scale Programmable Logic Controllers

Dragon Capital Group Subsidiary Awarded Contract for Central Control System Upgrade at Huinan Waterworks Facilities

Shanghai City North Gas Company, Ltd. to Use Dragon Capital Group's Gas Information System for Gas Valve Grouping Project

DoMark Internatioxnal, Inc. (DOMK)

The QualityStocks Daily Newsletter would like to spotlight DoMark International, Inc. (DOMK). Today, DoMark International, Inc. closed trading at $0.0442, up 2.31%, on 217,635 volume with 17 trades. The stock’s average daily volume over the past 60 days is 340,195, and its 52-week low/high is $0.0322/$0.535.

DoMark International, Inc. (DOMK) is focused on researching, evaluating, and acquiring profitable private firms in the business segments of sports, technology, medical, energy, and business services. By providing the financial and human capital necessary to deal with overwhelming administrative, planning, governance, compliance, and regulatory challenges, its newly acquired partners can focus their energy and flourish.

Through its wholly owned subsidiary, SolaWerks, Inc., DoMark is committed to revolutionizing the efficiency and capabilities of a new generation of mobile devices. The subsidiary's current focus is on developing and distributing the SolaPad, a combined cover and charging system for Apple's iPad, and the SolaCase, a combined cover and charging system for all versions of Apple's iPhone.

Musclefoot, Inc., another wholly owned subsidiary of DoMark, is engaged in the distribution, marketing, and sale of Barefoot Science, the revolutionary patented foot care system designed to relieve foot and back pain as well as improve athletic performance. With a strong commitment to customer service and security, DoMark plans to expand its marketing relationships across a far broader product set.

The management team has positioned the company to capitalize on emerging opportunities by working with the world's most forward-thinking companies to develop and market game-changing products with the promise of long-term financial growth. Leveraging the expertise of its team, the company continues to evaluate acquisition candidates and products targeting underserved markets to increase its growth potential. Disclaimer

DoMark International, Inc. Blog

DoMark International, Inc. News:

DoMark Increases Holding in Imagic Ltd. Ahead of SmartLink Global Launch

DoMark Acquires Unique Wireless Portable Plug and Print Patent Pending Printer for Smartphone/Digital Cameras

DoMark International Inc. Purchases 20% of Zaktek Ltd.

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

StockMister
(FMYR)

2.

OtcWizard
(CTDT)

3.

PennyStocks24
(TDEY)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251